drugset / Trial / NCT02052531

Evaluation of the Antipruritic Effect of PAC-14028 Cream in Skin Pruritus

NCT02052531

Phase 2 Completed 74 enrolled Amorepacific Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study was to find a clinically appropriate dose of PAC-14028 cream by comparatively evaluating the efficacy and safety of PAC-14028 cream of Amorepacific Corporation in patients with dermal pruritus.

Timeline

Start
2013-01
Primary completion
2013-06
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Subject PAC-14028 Unknown 0.3 % Topical
Subject PAC-14028 Unknown 1 % Topical

Indications

No indication recorded.